JP2021501587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501587A5 JP2021501587A5 JP2020524366A JP2020524366A JP2021501587A5 JP 2021501587 A5 JP2021501587 A5 JP 2021501587A5 JP 2020524366 A JP2020524366 A JP 2020524366A JP 2020524366 A JP2020524366 A JP 2020524366A JP 2021501587 A5 JP2021501587 A5 JP 2021501587A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- domain
- seq
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 68
- 102000025171 antigen binding proteins Human genes 0.000 claims description 31
- 108091000831 antigen binding proteins Proteins 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 230000003834 intracellular effect Effects 0.000 claims description 29
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 24
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581466P | 2017-11-03 | 2017-11-03 | |
| US62/581,466 | 2017-11-03 | ||
| PCT/IB2018/058642 WO2019087151A1 (en) | 2017-11-03 | 2018-11-02 | Cd38-directed chimeric antigen receptor constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501587A JP2021501587A (ja) | 2021-01-21 |
| JP2021501587A5 true JP2021501587A5 (enExample) | 2021-12-09 |
Family
ID=64277751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524366A Pending JP2021501587A (ja) | 2017-11-03 | 2018-11-02 | Ｃｄ３８指向性キメラ抗原受容体構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11760806B2 (enExample) |
| EP (1) | EP3704156A1 (enExample) |
| JP (1) | JP2021501587A (enExample) |
| KR (1) | KR20200076732A (enExample) |
| CN (1) | CN111542545A (enExample) |
| AU (1) | AU2018362014A1 (enExample) |
| CA (1) | CA3080109A1 (enExample) |
| WO (1) | WO2019087151A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019173837A1 (en) | 2018-03-09 | 2019-09-12 | Sorrento Therapeutics, Inc. | Dimeric antigen receptors (dar) |
| CA3103114A1 (en) * | 2018-06-20 | 2019-12-26 | Sorrento Therapeutics, Inc. | Variant antibody that binds cd38 |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| JP2022538461A (ja) * | 2019-07-01 | 2022-09-02 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８およびｃｄ３に結合するヘテロ二量体抗体 |
| WO2021009263A1 (en) * | 2019-07-16 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for cd38 and uses thereof |
| WO2021016621A1 (en) | 2019-07-25 | 2021-01-28 | Celularity Inc. | Populations of natural killer cells comprising a cd38 chimeric antigen receptor |
| EP4225799A4 (en) * | 2020-10-12 | 2024-11-20 | Sorrento Therapeutics, Inc. | CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS |
| CN113663061A (zh) * | 2021-08-04 | 2021-11-19 | 上海优卡迪生物医药科技有限公司 | Cd38在制备car-t药物中的应用 |
| CN113893338A (zh) * | 2021-11-04 | 2022-01-07 | 苏州大学附属第一医院 | Cd38 car-t细胞在慢性粒细胞白血病急髓变中的应用 |
| AU2023373900A1 (en) * | 2022-11-02 | 2025-05-15 | Medisix Therapeutics, Inc. | Methods and systems for production of engineered t-cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0651805B1 (en) * | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| JP6673838B2 (ja) | 2014-02-14 | 2020-04-01 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
| EP3172228B1 (en) | 2014-07-25 | 2019-02-27 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| WO2016044811A1 (en) * | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
| CN105802975B (zh) * | 2014-12-31 | 2020-04-14 | 浙江大学 | 靶向her2阳性肿瘤的细胞制备物及其用途 |
| CN107249604A (zh) * | 2014-12-31 | 2017-10-13 | 人类起源公司 | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| WO2016164656A1 (en) * | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| EP3283083A4 (en) * | 2015-04-15 | 2018-10-31 | Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center | Hepatic arterial infusion of car-t cells |
| WO2017025323A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| GB201518817D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| AU2016341321A1 (en) * | 2015-10-23 | 2018-06-07 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| KR102664453B1 (ko) | 2017-02-21 | 2024-05-10 | 주식회사 유틸렉스 | Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법 |
| WO2019173837A1 (en) * | 2018-03-09 | 2019-09-12 | Sorrento Therapeutics, Inc. | Dimeric antigen receptors (dar) |
| AU2019310430A1 (en) * | 2018-07-23 | 2021-02-25 | Magenta Therapeutics, Inc. | Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy |
| AU2019312200B2 (en) * | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
-
2018
- 2018-11-02 KR KR1020207015716A patent/KR20200076732A/ko not_active Withdrawn
- 2018-11-02 CN CN201880085146.7A patent/CN111542545A/zh active Pending
- 2018-11-02 EP EP18801058.1A patent/EP3704156A1/en not_active Withdrawn
- 2018-11-02 AU AU2018362014A patent/AU2018362014A1/en not_active Abandoned
- 2018-11-02 JP JP2020524366A patent/JP2021501587A/ja active Pending
- 2018-11-02 CA CA3080109A patent/CA3080109A1/en active Pending
- 2018-11-02 WO PCT/IB2018/058642 patent/WO2019087151A1/en not_active Ceased
- 2018-11-02 US US16/179,850 patent/US11760806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501587A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| AU2017384900B2 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| D’Aloia et al. | CAR-T cells: the long and winding road to solid tumors | |
| JP2019525738A5 (enExample) | ||
| Gross et al. | Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy | |
| JP2024099850A5 (enExample) | ||
| Zhao et al. | Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential | |
| JP2018506981A5 (enExample) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2019537433A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| JP2019513370A5 (enExample) | ||
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| JP2018503380A5 (enExample) | ||
| JP2020515239A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2019531056A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| AU2020314509A1 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof |